Literature DB >> 11388687

Adenosine enhances glial glutamate efflux via A2a adenosine receptors.

X X Li1, T Nomura, H Aihara, T Nishizaki.   

Abstract

The present study investigated the effect of adenosine on glial glutamate efflux. Adenosine (from 1 nM to 100 microM) enhanced the release from cultured rat glial cells in a bell-shaped dose-responsive manner for the hippocampus and in a dose-dependent manner for the superior colliculus, and a similar increase was obtained with the A2a adenosine receptor agonist, 2-p-(2-carboxyethyl) phenethylamino-5'-N-ethylcarboxamidoadenosine hydrochloride (CGS21680), but not with the A1 adenosine receptor agonist, N6-cyclohexyladenosine (CHA). Adenosine and CGS21680 also enhanced glutamate efflux from Xenopus oocytes injected with the poly (A)+ mRNAs derived from cultured glial cells for the hippocampus and the superior colliculus together with and without the A2a adenosine receptor mRNA, but instead such increase was not found in oocytes expressing A2a adenosine receptors alone. The results of the present study thus suggest that adenosine enhances glutamate efflux from glial cells via A2a adenosine receptors, and this may represent a mechanism underlying the facilitatory action of adenosine on hippocampal and superior colliculus neurotransmissions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11388687     DOI: 10.1016/s0024-3205(00)01036-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  22 in total

1.  Binding of adenosine receptor ligands to brain of adenosine receptor knock-out mice: evidence that CGS 21680 binds to A1 receptors in hippocampus.

Authors:  Linda Halldner; Luisa V Lopes; Elisabetta Daré; Karin Lindström; Björn Johansson; Catherine Ledent; Rodrigo A Cunha; Bertil B Fredholm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-18       Impact factor: 3.000

Review 2.  Purinoceptors on neuroglia.

Authors:  Alexei Verkhratsky; Alexei Verkhrasky; Oleg A Krishtal; Geoffrey Burnstock
Journal:  Mol Neurobiol       Date:  2009-03-13       Impact factor: 5.590

Review 3.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

Review 4.  Physiology of Astroglia.

Authors:  Alexei Verkhratsky; Maiken Nedergaard
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

Review 5.  Glial adenosine kinase--a neuropathological marker of the epileptic brain.

Authors:  Eleonora Aronica; Ursula S Sandau; Anand Iyer; Detlev Boison
Journal:  Neurochem Int       Date:  2013-02-04       Impact factor: 3.921

Review 6.  Adenosine signaling and function in glial cells.

Authors:  D Boison; J-F Chen; B B Fredholm
Journal:  Cell Death Differ       Date:  2009-09-18       Impact factor: 15.828

7.  Binding of the prototypical adenosine A(2A) receptor agonist CGS 21680 to the cerebral cortex of adenosine A(1) and A(2A) receptor knockout mice.

Authors:  Luísa V Lopes; Linda Halldner; Nelson Rebola; Björn Johansson; Catherine Ledent; Jian Fan Chen; Bertil B Fredholm; Rodrigo A Cunha
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

8.  Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Anna R Carta; Anil Kachroo; Nicoletta Schintu; Kui Xu; Michael A Schwarzschild; Jadwiga Wardas; Micaela Morelli
Journal:  J Neurochem       Date:  2009-10-08       Impact factor: 5.372

9.  Caffeine has a dual influence on NMDA receptor-mediated glutamatergic transmission at the hippocampus.

Authors:  Robertta S Martins; Diogo M Rombo; Joana Gonçalves-Ribeiro; Carlos Meneses; Vladimir P P Borges-Martins; Joaquim A Ribeiro; Sandra H Vaz; Regina C C Kubrusly; Ana M Sebastião
Journal:  Purinergic Signal       Date:  2020-10-06       Impact factor: 3.765

10.  The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release.

Authors:  Sondra T Bland; Mark R Hutchinson; Steven F Maier; Linda R Watkins; Kirk W Johnson
Journal:  Brain Behav Immun       Date:  2009-02-03       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.